Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals
EPIC: OXP
Latest Price: 3.95  (0.64% Ascending)
52-week High: 4.13
52-week Low: 1.05
Market Cap: 35.45M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Oxford Pharmascience
www.oxfordpharmascience.com

We are a specialist pharmaceutical technology company developing and licensing solutions to add value to off patent and soon to be off patent drugs. Our technology portfolio includes delivery systems for liquid suspensions, solid state suspensions (soft chews) and superior chewable tablets, as well as our proprietary technologies OxpZero™ which allows for complete taste masking and OxpTarget™ which allows for precise drug delivery.

Full Oxford Pharmascience profile here
Pdf

Oxford Pharmascience partners with London University on drug delivery deal

31st Aug 2011, 3:38 am by Jon Mainwaring

Oxford Pharmascience (LON:OXP) announced this morning that it has signed a deal with the University of London’s School of Pharmacy, giving the firm the option to license and research an advanced colonic drug delivery technology.

Oxford Pharmascience is already a specialist in various forms of drug delivery technology, but 18-month option will give it the opportunity to explore a whole new area of drug delivery. The platform technology, developed by the London School of Pharmacy’s Abdul Basit, provides for superior controlled delivery of drugs to the colon.

Targeting of drugs to the colon can help achieve localised therapy for such health problems as irritable bowel syndrome, constipation, diarrhoea, infection and carcinoma. But the colon can also be targeted as a way of getting drugs into the body that are designed to tackle health issues away from the bowel. 

Oxford Pharmascience said that an international patent application for the technology was filed in 2007, with a priority claim to an earlier British case filed in 2006 that is now entering the national and regional phase.

"Accessing cutting edge technology from a strong academic partner such as the London School of Pharmacy gives Oxford Pharmascience significant capability to innovate and extend the lifecycle of off-patent and soon to be off-patent drugs," said Marcelo Bravo, Oxford Pharmascience’s chief technology officer.

"The superior colon targeting and drug release profile achieved by London School of Pharmacy’s drug delivery technology will enable us to develop a next generation application for a major drug category across markets worldwide.”

 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here